Protocol Ledger

NCT05116241 · Phase II · COMPLETED

Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

Interventional Phase II clinical trial protocol NCT05116241 sponsored by ILiAD Biotechnologies in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-11 Enrollment: 368 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05116241
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)368 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05116241
Protocol FieldVerified Registry Value
NCT IdentifierNCT05116241
Consolidated Lead SponsorILiAD Biotechnologies
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment368 participants (ACTUAL)
Registered Start Date2021-11-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05116241
Hospital Research SiteLocationSite Profile
Addenbrooke's HospitalCambridge, United KingdomOpen Hospital Dossier ->
University Hospital Southampton NHS Foundation TrustSouthampton, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI